

- **Full Name:** Keiichi Fujiwara
  - **Current Position & Affiliation:** Professor, Gynecologic Oncology, Saitama Medical University and International University of Health and Welfare
  - **Country:** Japan
- 

**• Educational Background:**

- 1979 Okayama University School of Medicine, MD
- 1987 Okayama University School of Medicine, PhD

**• Professional Experience:**

- 2022 - Present, Professor. Saitama Medical University (SMUIMC) and International University of Health and Welfare
- 2007 - 2022 Professor and Director, Gynecologic Oncology, SMUIMC
- 1990 - 2006 Department of OBGYN Kawasaki Medical School
- 1988 - 1990 Department of Gynecologic Oncology and Experimental Radiation Oncology, Wake Forest University

**• Professional Organizations:**

- 2022 – Present International Gynecologic Cancer Society (IGCS), President
- 2018-2020 Chair, Gynecologic Cancer Intergroup (GCIIG)
- Founding Member and President, Gynecologic Oncology Trial and Investigation Consortium (GOTIC)

**• Main Scientific Publications:**

1. Nagao D, **Fujiwara K**, Yamamoto K, Tanabe H, Okamoto A, Takehara K, Saito M, Fujiwara H, Tan DSP, Yamaguchi S, Adachi S, Kikuchi A, Hirasawa T, Yokoi T, Nagai T, Sato T, Kamiura S, Fujishita A, Loong WW, Chan K Syks P, Olawaye A, Ryu SY, Shigeta H, Kondo E, Yokoyama Y, Matsumoto T, Hasegawa K, Enomoto, T. Intraperitoneal Carboplatin for Ovarian Cancer – A Phase 2/3 Study. Published April 21, 2023 NEJM Evid 2023;2(5) DOI: 10.1056/EVIDoa2200225 VOL. 2 NO. 5
2. Tan D, Fujiwara N, **Fujiwara K**, Beale P, Kim JW, Ng J, Kim SI, Evans A, Kim BG; The Asia-Pacific Gynecologic Oncology Trials Group (APGOT): building a Pan-Asian and Oceania women's cancer research organization. Asia-Pacific Gynecologic Oncology Trials Group (APGOT). Int J Gynecol Cancer. 2023 Mar 13:ijgc-2022-004236. doi: 10.1136/ijgc-2022-004236.
3. Vergote I, Gonzalez-Martin A, Lorusso D, Gourley C, Mirza MR, Kurtz JE, Okamoto A, Moore K, Kridelka F, McNeish I, Reuss A, Votan B, du Bois A, Mahner S, Ray-Coquard I, Kohn EC, Berek JS, Tan DSP, Colombo N, Zang R, Concini N, O'Donnell D, Rauh-Hain A, Herrington CS,

- Marth C, Poveda A, **Fujiwara K**, Stuart GCE, Oza AM, Bookman MA; participants of the 6th Gynecologic Cancer InterGroup (GCIG) Ovarian Cancer Consensus Conference on Clinical Research. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup. *Lancet Oncol*. 2022 Aug;23(8):e374-e384. doi: 10.1016/S1470-2045(22)00139-5.
4. Makker V, Colombo N, Casado Herráez A, Santin AD, Colomba E, Miller DS, **Fujiwara K**, Pignata S, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Ushijima K, Sakata J, Yonemori K, Kim YM, Guerra EM, Sanli UA, McCormack MM, Smith AD, Keefe S, Bird S, Dutta L, Orłowski RJ, Lorusso D; Study 309–KEYNOTE-775 Investigators. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer. *N Engl J Med*. 2022 Feb 3;386(5):437-448. doi: 10.1056/NEJMoa2108330. Epub 2022 Jan 19. PMID: 35045221
  5. Monk BJ, Parkinson C, Lim MC, O'Malley DM, Oaknin A, Wilson MK, Coleman RL, Lorusso D, Bessette P, Ghamande S, Christopoulou A, Provencher D, Prendergast E, Demirkiran F, Mikheeva O, Yeku O, Chudecka-Glaz A, Schenker M, Littell RD, Safra T, Chou HH, Morgan MA, Drochýtek V, Barlin JN, Van Gorp T, Ueland F, Lindahl G, Anderson C, Collins DC, Moore K, Marme F, Westin SN, McNeish IA, Shih D, Lin KK, Goble S, Hume S, **Fujiwara K**, Kristeleit RS. A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). *J Clin Oncol*. 2022 Jun 6;JCO2201003. doi: 10.1200/JCO.22.01003. Online ahead of print. PMID: 35658487
  6. Tewari KS, Monk BJ, Vergote I, Miller A, de Melo AC, Kim HS, Kim YM, Lisyanskaya A, Samouëlian V, Lorusso D, Damian F, Chang CL, Gotovkin EA, Takahashi S, Ramone D, Pikiel J, Maćkowiak-Matejczyk B, Guerra Alía EM, Colombo N, Makarova Y, Rischin D, Lheureux S, Hasegawa K, **Fujiwara K**, Li J, Jamil S, Jankovic V, Chen CI, Seebach F, Weinreich DM, Yancopoulos GD, Lowy I, Mathias M, Fury MG, Oaknin A; Investigators for GOG Protocol 3016 and ENGOT Protocol En-Cx9. Survival with Cemiplimab in Recurrent Cervical Cancer. *N Engl J Med*. 2022 Feb 10;386(6):544-555. doi: 10.1056/NEJMoa2112187. PMID: 35139273
  7. Hamanishi J, Takeshima N, Katsumata N, Ushijima K, Kimura T, Takeuchi S, Matsumoto K, Ito K, Mandai M, Nakai H, Sakuragi N, Watari H, Takahashi N, Kato H, Hasegawa K, Yonemori K, Mizuno M, Takehara K, Niikura H, Sawasaki T, Nakao S, Saito T, Enomoto T, Nagase S, Suzuki N, Matsumoto T, Kondo E, Sonoda K, Aihara S, Aoki Y, Okamoto A, Takano H, Kobayashi H, Kato H, Terai Y, Takazawa A, Takahashi Y, Namba Y, Aoki D, **Fujiwara K**, Sugiyama T, Konishi I. Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA). *J Clin Oncol*. 2021 Sep 2;JCO2100334. doi: 10.1200/JCO.21.00334. Online ahead of print. PMID: 34473544
  8. Monk BJ, Colombo N, Oza AM, **Fujiwara K**, Birrer MJ, Randall L, Poddubskaya EV, Scambia G, Shparyk YV, Lim MC, Bhoola SM, Sohn J, Yonemori K, Stewart RA, Zhang X, Perkins Smith J, Linn C, Ledermann JA. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial. *Lancet Oncol*. 2021 Sep;22(9):1275-1289. doi: 10.1016/S1470-2045(21)00342-9. Epub 2021 Aug 4. PMID: 34363762